“Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma” has been added to your cart. View cart

Article: Novel therapeutic molecular targets in lung cancer: non-V600 mutant and mutant

€3.03

SKU: product-article-10757 Category: General

Description
Reviews (0)

Description

Novel therapeutic molecular targets in lung cancer: non-V600 mutant and mutant

Reviews

There are no reviews yet.

Be the first to review “Article: Novel therapeutic molecular targets in lung cancer: non-V600 mutant and mutant”

You must be logged in to post a review.

Top

Article: Novel therapeutic molecular targets in lung cancer: non-V600 mutant and mutant

Description

Reviews

Related products

Article: Highlights in respiratory oncology

Article: Highlights in urologic cancer

Article: Highlights in squamous cell carcinoma of the head and neck

Article: Highlights in breast cancer